K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 31.85 HKD -2.3%
Market Cap: 8.9B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

KeyMed Biosciences Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Inventory
ÂĄ56.4m
CAGR 3-Years
102%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Inventory
ÂĄ3B
CAGR 3-Years
72%
CAGR 5-Years
92%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Inventory
ÂĄ690.4m
CAGR 3-Years
-14%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Inventory
ÂĄ905.5m
CAGR 3-Years
31%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Inventory
ÂĄ15.7B
CAGR 3-Years
33%
CAGR 5-Years
43%
CAGR 10-Years
57%
Imeik Technology Development Co Ltd
SZSE:300896
Inventory
ÂĄ49.8m
CAGR 3-Years
23%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
8.9B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

Intrinsic Value
17.51 HKD
Overvaluation 45%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Inventory?
Inventory
56.4m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Inventory amounts to 56.4m CNY.

What is KeyMed Biosciences Inc's Inventory growth rate?
Inventory CAGR 3Y
102%

Over the last year, the Inventory growth was 27%. The average annual Inventory growth rates for KeyMed Biosciences Inc have been 102% over the past three years .

Back to Top